Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma

Melanoma is one of the most fatal cancers, and its incidence is increasing worldwide. Thanks to the better understanding of the molecular mechanisms involved in the pathogenesis of melanoma, recently new targeted agents have been developed. In this article, we review the current state of knowledge o...

Descripción completa

Detalles Bibliográficos
Autores principales: Russo, Irene, Zorzetto, Ludovica, Chiarion Sileni, Vanna, Alaibac, Mauro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332919/
https://www.ncbi.nlm.nih.gov/pubmed/30693134
http://dx.doi.org/10.1155/2018/5036213
_version_ 1783387459824910336
author Russo, Irene
Zorzetto, Ludovica
Chiarion Sileni, Vanna
Alaibac, Mauro
author_facet Russo, Irene
Zorzetto, Ludovica
Chiarion Sileni, Vanna
Alaibac, Mauro
author_sort Russo, Irene
collection PubMed
description Melanoma is one of the most fatal cancers, and its incidence is increasing worldwide. Thanks to the better understanding of the molecular mechanisms involved in the pathogenesis of melanoma, recently new targeted agents have been developed. In this article, we review the current state of knowledge of clinical presentation, mechanisms, and management of the most common cutaneous side effects observed during treatment with targeted and immunological therapies approved for advanced melanoma. We include discussion of BRAF/MEK inhibitors and immune-checkpoint inhibitors, notably CTLA-4 and PD-1 inhibitors.
format Online
Article
Text
id pubmed-6332919
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-63329192019-01-28 Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma Russo, Irene Zorzetto, Ludovica Chiarion Sileni, Vanna Alaibac, Mauro Scientifica (Cairo) Review Article Melanoma is one of the most fatal cancers, and its incidence is increasing worldwide. Thanks to the better understanding of the molecular mechanisms involved in the pathogenesis of melanoma, recently new targeted agents have been developed. In this article, we review the current state of knowledge of clinical presentation, mechanisms, and management of the most common cutaneous side effects observed during treatment with targeted and immunological therapies approved for advanced melanoma. We include discussion of BRAF/MEK inhibitors and immune-checkpoint inhibitors, notably CTLA-4 and PD-1 inhibitors. Hindawi 2018-12-30 /pmc/articles/PMC6332919/ /pubmed/30693134 http://dx.doi.org/10.1155/2018/5036213 Text en Copyright © 2018 Irene Russo et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Russo, Irene
Zorzetto, Ludovica
Chiarion Sileni, Vanna
Alaibac, Mauro
Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma
title Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma
title_full Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma
title_fullStr Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma
title_full_unstemmed Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma
title_short Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma
title_sort cutaneous side effects of targeted therapy and immunotherapy for advanced melanoma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332919/
https://www.ncbi.nlm.nih.gov/pubmed/30693134
http://dx.doi.org/10.1155/2018/5036213
work_keys_str_mv AT russoirene cutaneoussideeffectsoftargetedtherapyandimmunotherapyforadvancedmelanoma
AT zorzettoludovica cutaneoussideeffectsoftargetedtherapyandimmunotherapyforadvancedmelanoma
AT chiarionsilenivanna cutaneoussideeffectsoftargetedtherapyandimmunotherapyforadvancedmelanoma
AT alaibacmauro cutaneoussideeffectsoftargetedtherapyandimmunotherapyforadvancedmelanoma

Ejemplares similares